Adeno-associated viral vectors (AAV vectors) are essential tools for delivering gene therapy to patients and are usually manufactured using plasmid-based approaches. However, there are challenges with ...

The publication introduces a genetic identification system that enables plasmids to carry embedded documentation, improving traceability, verification, and secure exchange in biotech research and ...

ZHENJIANG, China, Dec. 7, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio ...

DUBLIN, Nov. 30, 2020 /PRNewswire/ -- The "CRISPR Technology Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Scientists use plasmids as the leading gene delivery technology for a variety of research and clinical applications related to gene therapy. Traditional approaches to plasmid creation often result in ...

SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development and ...

IMUNON announces promising Phase 1 results for IMNN-101, a DNA plasmid vaccine demonstrating enhanced durability and potential advantages over mRNA vaccines. Phase 1 clinical trial results of IMNN-101 ...

DNA plasmid technology has many applications. Inovio’s Covid-19 vaccine may still have a global market. Inovio potential HPV related therapies look headed for success. Glioblastoma therapy success is ...

Inovio reported positive Phase 3 VGX-3100 data. In addition to treating cervical dysplasia, label expansion is likely. DNA plasmid technology is poised to create a broad array of commercial therapies.

For Research Use Only. Not for use in diagnostic procedures. The purification of plasmid DNA (pDNA) is essential in molecular biology research. Over the years, plasmid DNA isolation technology has ...

As it continues to push its DNA-based interleukin-12 (IL-12) therapy through phase 2 trials and hopes to take on the mRNA vaccine juggernauts, Celsion Corporation has decided now is the time for a ...